Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the ...
Q32 Bio price target lowered to $20 from $80 at Oppenheimer
Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.
Hosted on MSN10h
Wells Fargo Downgrades Q32 Bio (QTTB)
Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...
The Pharma Letter16h
Q32 Bio tanks on mixed bempikibart program update
US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...
Hosted on MSN22h
Leerink Partners Downgrades Q32 Bio (QTTB)
Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...
Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment
Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...